ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

  • Abstract Number: 565 • 2018 ACR/ARHP Annual Meeting

    Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis

    Thierry Dervieux1, Marie Grosjean2, Chuang Jiang3,4, Kelley Brady1, Kjeld Schmiegelow2, Joel Kremer5 and Jun Yang4, 1Exagen Diagnostics, Inc., Vista, CA, 2University Hospital Rigshospitalet, Copenhagen, Denmark, 3Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China, 4Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Methotrexate (MTX) is anti-folate activated to MTX polyglutamates (MTXPGs). MTX metabolism includes multiple enzyme-mediated reactions and genetic polymorphisms in these genes are linked to…
  • Abstract Number: 571 • 2018 ACR/ARHP Annual Meeting

    United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab

    Aaron Broadwell1, Vance Bray2, Douglas Conaway3, Joy Schechtman4, Alan J. Kivitz5, Dennis Parenti6, Shawn Black6, Stephen Xu7, Wayne Langholff7 and Shelly Kafka6, 1Rheumatology Osteoporosis Specialists, Shreveport, LA, 2Denver Arthritis Clinic, Denver, CO, 3Carolina Health Specialists, Myrtle Beach, SC, 4Sun Valley Arthritis Center, Peoria, AZ, 5Altoona Arthritis & Osteoporosis Center, Altoona, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
  • Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting

    Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study

    Naohiro Sugitani1,2, Eiichi Tanaka1, Eisuke Inoue1,3, Eri Sugano1, Kumiko Saka1, Moeko Ochiai1, Rei Yamaguchi1, Yoko Shimizu1, Naoki Sugimoto1, Katsunori Ikari1, Ayako Nakajima1,2, Atsuo Taniguchi1 and Hisashi Yamanaka4, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 3Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 4Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
  • Abstract Number: 608 • 2018 ACR/ARHP Annual Meeting

    Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission

    Takeshi Suzuki, Takayasu Ando, Shoshi Shinagawa, Machiko Mizushima, Tomohiko Shibata and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Recently, it is recommended that tapering csDMARDs could be considered If a patient is in persistent remission. However, the methods of tapering csDMARDs including…
  • Abstract Number: 616 • 2018 ACR/ARHP Annual Meeting

    Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX

    Pamela B. Rosenthal1, Jeffrey S. Berger2 and Bruce N. Cronstein1, 1Rheumatology, New York University School of Medicine, New York, NY, 2Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: Low dose weekly MTX remains the anchor drug for treatment of Rheumatoid Arthritis. The principal mechanism by which MTX suppresses inflammation in Rheumatoid Arthritis…
  • Abstract Number: 539 • 2017 ACR/ARHP Annual Meeting

    Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis

    Sahar Janjua1, Andreea Bujor1, Michael P. LaValley2, Josefina Duran3, Jürgen Braun4 and David T. Felson5, 1Department of Rheumatology, Boston Medical Center, Boston, MA, 2Boston University School of Public Health, Boston, MA, 3Pontificia Universidad Católica de Chile, Santiago, Chile, 4Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Methotrexate (MTX) is the mainstay first-line therapy for rheumatoid arthritis (RA), and it can be given orally or parenterally. Bioavailability of oral MTX may…
  • Abstract Number: 1438 • 2017 ACR/ARHP Annual Meeting

    Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial

    Alain Saraux1, Christophe Hudry2, Elena Zinovieva3 and Hélène Herman-Demars3, 1Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 2AP-HP Hôpital Cochin, Paris, France, 3Medical Department Nordic Pharma, Paris, France

    Background/Purpose: In inflammatory rheumatic diseases, pharmacokinetics of MTX may be modified by patients’ weight [1]. The rheumatologists are though reluctant to prescribe a high dosage…
  • Abstract Number: 1738 • 2017 ACR/ARHP Annual Meeting

    The Pattern of Proinflamatory Cytokine Expression By CD4+ T Lymphocytes Segregates the Clinical Response to Methotrexate in Recently Diagnosed Rheumatoid Arthritis Patients

    Jorge Monserrat Sanz1, Ana Maria Gómez Lahoz2, Cristina Bohórquez Heras3, Maria Dolores Sosa Reina2, Atusa Movasat3, Ana Pérez Gómez3, Lucía Ruiz Gutiérrez3, Ana Sánchez Atrio3, Eduardo Cuende Quintana3, Maria José León3, David Diaz2, Fernando Albarrán Hernández3 and Melchor Alvarez-Mon2,3, 1Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares. Madrid, Spain, 2Laboratory of Inmune System Diseases, Deparment of Medicine and Medical Specialties. IRYCIS. University of Alcalá. Madrid. Spain, Alcalá de Henares, Madrid, Spain, 3University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain

    Background/Purpose: Mechanisms regulating the autoimmune response in rheumatoid arthritis (RA) are not well understood. However, it is known that T CD4+ lymphocytes play a pivotal…
  • Abstract Number: 2380 • 2017 ACR/ARHP Annual Meeting

    The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes

    Malack Alachkar1, T Mathialahan2, Sandra Walsh2 and Vun Lim3, 1Rheumatology, The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 2Gastroenterology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom, 3Rheumatology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom

    Background/Purpose: FibroScan (FS) is a non-invasive investigation that allows assessment of possible liver fibrosis by measuring liver stiffness. There are studies which confirm that MTX-related…
  • Abstract Number: 2479 • 2017 ACR/ARHP Annual Meeting

    Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis

    Mark C. Genovese1, Erin K. Mangan2, Toshio Kimura2, Melitza Iglesias-Rodriguez3 and Tom W.J. Huizinga4, 1Stanford University Medical Center, Palo Alto, CA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Cambridge, MA, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3, 52-week MOBILITY study (NCT01061736), sarilumab (150 or 200 mg subcutaneously every 2…
  • Abstract Number: 2480 • 2017 ACR/ARHP Annual Meeting

    Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies

    Mark C. Genovese1, Erin K. Mangan2, Jonathan Fay2, Toshio Kimura2, Hubert van Hoogstraten3 and Roy Fleischmann4, 1Stanford University Medical Center, Palo Alto, CA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Sanofi Genzyme, Bridgewater, NJ, 4Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rɑ. Efficacy and safety of sarilumab (150 or 200 mg subcutaneously every 2 wks [q2w]) + conventional…
  • Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting

    CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis

    Vikas Gupta1, Shobhita Katiyar2, Ankita Singh2, Ramnath Misra1 and Amita Aggarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…
  • Abstract Number: 433 • 2017 ACR/ARHP Annual Meeting

    Predictors of Earlier Biologic Initiation Among Patients with Rheumatoid Arthritis Starting Methotrexate

    Michael D. George1, Brian Sauer2, Chia-Chen Teng, MS2, Grant Cannon2, Bryant R. England3, Gail S. Kerr4, Ted R. Mikuls5 and Joshua Baker6, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 4VAMC, Georgetown University, Washington, DC, 5Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Biologic therapy for the treatment of RA has increased dramatically and has substantially increased costs of care. This study aimed to identify factors associated…
  • Abstract Number: 443 • 2017 ACR/ARHP Annual Meeting

    Methotrexate Treatment Strategies in an Early Rheumatoid Arthritis Cohort

    Sasha Bernatsky1, Orit Schieir2, Cristiano S. Moura3, Marie-France Valois4, Susan J. Bartlett5, Carol A Hitchon6, Janet E. Pope7, Gilles Boire8, Boulos Haraoui9, Edward C. Keystone10, Diane Tin11, Carter Thorne12 and Vivian P. Bykerk13, 1Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 31Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 6University of Manitoba, Winnipeg, MB, Canada, 7Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 8Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 9Institute de Rheumatologie, Montreal, QC, Canada, 10Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 11The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 12University of Toronto, Newmarket, ON, Canada, 132-005, Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Methotrexate (MTX) is recommended as part of initial therapy in early RA, but practices range widely. The objective of this analysis was to describe…
  • Abstract Number: 461 • 2017 ACR/ARHP Annual Meeting

    Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?

    Sasha Bernatsky1, Orit Schieir2, Cristiano S. Moura3, Marie-France Valois4, Susan J. Bartlett5, Carol A Hitchon6, Janet E. Pope7, Gilles Boire8, Boulos Haraoui9, Edward C. Keystone10, Diane Tin11, Carter Thorne12 and Vivian P. Bykerk13, 1Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University, Montreal, ON, Canada, 31Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 4McGill University, Montreal, QC, Canada, 5Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 8Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 9Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 10University of Toronto, Toronto, ON, Canada, 11The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 12University of Toronto, Newmarket, ON, Canada, 132-005, Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Our objective was to compare RA treatment strategies with conventional and biologic DMARDs after an initial MTX strategy was ineffective or associated with a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology